News from Novartis A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Feb 16, 2018, 16:09 ET Novartis new data show Cosentyx® improved quality of life over 5 years in two thirds of patients with moderate to severe plaque psoriasis

Novartis announced today additional results from the SCULPTURE study showing that two thirds of moderate to severe plaque psoriasis patients...


Feb 08, 2018, 01:22 ET Novartis receives FDA approval for Cosentyx® label update to include moderate to severe scalp psoriasis

Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Cosentyx® (secukinumab), the first...


Jan 31, 2018, 17:09 ET Novartis Announces NEJM Publication Of Updated Analysis From ELIANA Trial Showing Longer-Term Durable Remissions With Kymriah™ In Children, Young Adults With r/r ALL

Novartis today announced updated results from the pivotal ELIANA clinical trial of Kymriah™ (tisagenlecleucel), formerly CTL019, in relapsed or...


Jan 17, 2018, 01:18 ET Novartis granted US FDA Priority Review for Kymriah™ (tisagenlecleucel), formerly CTL019, for adults with r/r DLBCL

Novartis today announced that its supplemental Biologics License Application (sBLA) for Kymriah™ (tisagenlecleucel) suspension for intravenous...


Dec 22, 2017, 16:56 ET Novartis drug Tasigna® is approved by FDA as first and only CML therapy with Treatment-free Remission data in its label

Novartis announced today that the US Food and Drug Administration (FDA) approved the inclusion of Treatment-free Remission (TFR) data in the...


Dec 22, 2017, 07:30 ET Novartis' combination therapy Tafinlar® + Mekinist® granted FDA Priority Review for the adjuvant treatment of stage III BRAF V600 mutation-positive melanoma

Novartis announced today the US Food and Drug Administration (FDA) has accepted the Company's supplemental New Drug Application (sNDA) for filing,...


Dec 18, 2017, 09:00 ET Novartis multiple sclerosis therapy fingolimod granted FDA Breakthrough Therapy designation for pediatric MS

Novartis today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for fingolimod for the...


Dec 10, 2017, 10:47 ET Primary analysis results from Novartis pivotal JULIET trial show Kymriah™ (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer

Novartis today announced updated results from the JULIET clinical trial demonstrating sustained responses with Kymriah™ (tisagenlecleucel)...


Nov 13, 2017, 12:02 ET Novartis canakinumab (ACZ885) reduced cardiovascular risk by 25% in subgroup of CANTOS Phase III trial participants

Novartis today announced results from a new analysis of the Phase III CANTOS study presented by Dr. Paul Ridker at the American Heart Association...


Nov 10, 2017, 18:00 ET Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness

Novartis, a global leader in ophthalmology, announced further positive results from two Phase III studies of brolucizumab versus aflibercept....


Nov 07, 2017, 08:02 ET Novartis announces study data demonstrating Cosentyx® reduced signs and symptoms of psoriatic arthritis while inhibiting progression of joint structural damage

Novartis announced today results from the FUTURE 5 study showing Cosentyx® (secukinumab) reduced the signs and symptoms of psoriatic arthritis...


Oct 31, 2017, 02:23 ET Novartis submits application to FDA for Kymriah™ (tisagenlecleucel) in adult patients with r/r DLBCL, seeking second indication for first-ever FDA approved CAR-T therapy

Novartis today announced that the company has submitted a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration...


Oct 28, 2017, 03:15 ET Novartis pivotal data show children and adolescents with relapsing MS had an 82% lower relapse rate with fingolimod vs. interferon beta-1a

Novartis today announced results from the Phase III PARADIGMS study, investigating the safety and efficacy of fingolimod vs. interferon beta-1a, in...


Oct 18, 2017, 07:15 ET Novartis drug Promacta® shows long-term disease control for chronic/persistent immune thrombocytopenia (ITP)

Novartis today announced long-term study results supporting the positive safety and efficacy of Promacta (eltrombopag) in adults with...


Oct 11, 2017, 07:00 ET Novartis: Vivre avec le psoriasis : C'est PSOssible ? Résultats de l'enquête mondiale « Clear About Psoriasis »

L’enquête mondiale « Clear About Psoriasis » révèle à quel point une diminution des symptômes visibles du psoriasis est fondamentale pour que les...


Sep 19, 2017, 09:15 ET New analysis shows Entresto improved physical and social activity in patients with HFrEF

Novartis announced today results of a new post-hoc analysis, which found that Entresto® (sacubitril/valsartan) improved seven out of 10 types of...


Sep 13, 2017, 01:34 ET Novartis Cosentyx® sets the new benchmark in psoriasis with robust 5-year sustained efficacy and safety Phase III data

Novartis announced today first of its kind Phase III data showing Cosentyx® (secukinumab) delivered high and long-lasting skin clearance in...


Aug 30, 2017, 13:49 ET Multimedia Assets Now Available: Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah™ (tisagenlecleucel, CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice

Novartis announced today that the US Food and Drug Administration (FDA) has approved Kymriah™(tisagenlecleucel) suspension for intravenous...


Aug 30, 2017, 11:45 ET Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah™ (tisagenlecleucel, CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice

Novartis announced today that the US Food and Drug Administration (FDA) has approved Kymriah™(tisagenlecleucel) suspension for intravenous...


Aug 21, 2017, 16:30 ET Novartis launches first large-scale research study in multiple sclerosis that allows participants to contribute from smartphones

Novartis announced today the launch of a mobile research study for people with multiple sclerosis (MS) that collects data via their smartphone,...


Jul 20, 2017, 16:38 ET FDA Accepts Biologics License Application for AMG 334 (Erenumab), an Important Regulatory Milestone for Novartis

Novartis today announced that the US Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for AMG 334...


Jul 12, 2017, 17:25 ET Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL

Novartis announced today that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) unanimously (10-0) recommended...


Jun 23, 2017, 12:07 ET NEJM publishes full analysis of Rydapt® (midostaurin) Phase III RATIFY trial in newly diagnosed FLT3-mutated acute myeloid leukemia (AML)

Novartis today announced that full results from the Rydapt® (midostaurin) Phase III RATIFY (CALGB 10603 [Alliance]) clinical trial were published...


Jun 23, 2017, 02:41 ET Novartis pivotal CTL019 6-month follow-up data show durable remission rates in children, young adults with r/r B-cell ALL

Novartis today announced updated results from the ELIANA clinical trial demonstrating CTL019 (tisagenlecleucel) remission rates are maintained at...


Jun 22, 2017, 17:47 ET Novartis combination targeted therapy Tafinlar® + Mekinist® receives FDA approval for BRAF V600E mutant metastatic non-small cell lung cancer (NSCLC)

Novartis today announced the US Food and Drug Administration (FDA) approval of Tafinlar® (dabrafenib) in combination with Mekinist® (trametinib) to...